Literature DB >> 20181691

In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques.

Rory D de Vries1, Ken Lemon, Martin Ludlow, Stephen McQuaid, Selma Yüksel, Geert van Amerongen, Linda J Rennick, Bert K Rima, Albert D M E Osterhaus, Rik L de Swart, W Paul Duprex.   

Abstract

The global increase in measles vaccination has resulted in a significant reduction of measles mortality. The standard route of administration for the live-attenuated measles virus (MV) vaccine is subcutaneous injection, although alternative needle-free routes, including aerosol delivery, are under investigation. In vitro, attenuated MV has a much wider tropism than clinical isolates, as it can use both CD46 and CD150 as cellular receptors. To compare the in vivo tropism of attenuated and pathogenic MV, we infected cynomolgus macaques with pathogenic or attenuated recombinant MV expressing enhanced green fluorescent protein (GFP) (strains IC323 and Edmonston, respectively) via the intratracheal or aerosol route. Surprisingly, viral loads and cellular tropism in the lungs were similar for the two viruses regardless of the route of administration, and CD11c-positive cells were identified as the major target population. However, only the pathogenic MV caused significant viremia, which resulted in massive virus replication in B and T lymphocytes in lymphoid tissues and viral dissemination to the skin and the submucosa of respiratory epithelia. Attenuated MV was rarely detected in lymphoid tissues, and when it was, only in isolated infected cells. Following aerosol inhalation, attenuated MV was detected at early time points in the upper respiratory tract, suggesting local virus replication. This contrasts with pathogenic MV, which invaded the upper respiratory tract only after the onset of viremia. This study shows that despite in vitro differences, attenuated and pathogenic MV show highly similar in vivo tropism in the lungs. However, systemic spread of attenuated MV is restricted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181691      PMCID: PMC2863733          DOI: 10.1128/JVI.02633-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications.

Authors:  M R Hilleman
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

2.  Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation.

Authors:  Richard K Plemper; Richard W Compans
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 3.  Progress toward measles eradication in the region of the Americas.

Authors:  Ciro A De Quadros; Héctor Izurieta; Peter Carrasco; Monica Brana; Gina Tambini
Journal:  J Infect Dis       Date:  2003-05-15       Impact factor: 5.226

4.  V and C proteins of measles virus function as virulence factors in vivo.

Authors:  J B Patterson; D Thomas; H Lewicki; M A Billeter; M B Oldstone
Journal:  Virology       Date:  2000-02-01       Impact factor: 3.616

5.  Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production.

Authors:  D Naniche; A Yeh; D Eto; M Manchester; R M Friedman; M B Oldstone
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

Authors:  K J Stittelaar; T Kuiken; R L de Swart; G van Amerongen; H W Vos; H G Niesters; P van Schalkwijk; T van der Kwast; L S Wyatt; B Moss; A D Osterhaus
Journal:  Vaccine       Date:  2001-06-14       Impact factor: 3.641

7.  SLAM (CDw150) is a cellular receptor for measles virus.

Authors:  H Tatsuo; N Ono; K Tanaka; Y Yanagi
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

Review 8.  Immunization of children at risk of infection with human immunodeficiency virus.

Authors:  William J Moss; C John Clements; Neal A Halsey
Journal:  Bull World Health Organ       Date:  2003-03-11       Impact factor: 9.408

9.  Wild-type measles virus infection of primary epithelial cells occurs via the basolateral surface without syncytium formation or release of infectious virus.

Authors:  Martin Ludlow; Linda J Rennick; Severine Sarlang; Grzegorz Skibinski; Stephen McQuaid; Tara Moore; Rik L de Swart; W Paul Duprex
Journal:  J Gen Virol       Date:  2009-11-18       Impact factor: 3.891

10.  SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein.

Authors:  Koji Hashimoto; Nobuyuki Ono; Hironobu Tatsuo; Hiroko Minagawa; Makoto Takeda; Kaoru Takeuchi; Yusuke Yanagi
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  59 in total

1.  Canine distemper virus epithelial cell infection is required for clinical disease but not for immunosuppression.

Authors:  Bevan Sawatsky; Xiao-Xiang Wong; Sarah Hinkelmann; Roberto Cattaneo; Veronika von Messling
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques.

Authors:  Wen-Hsuan Lin; Diane E Griffin; Paul A Rota; Mark Papania; Stephen P Cape; David Bennett; Brian Quinn; Robert E Sievers; Charles Shermer; Kenneth Powell; Robert J Adams; Steven Godin; Scott Winston
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

3.  SLAM- and nectin-4-independent noncytolytic spread of canine distemper virus in astrocytes.

Authors:  Lisa Alves; Mojtaba Khosravi; Mislay Avila; Nadine Ader-Ebert; Fanny Bringolf; Andreas Zurbriggen; Marc Vandevelde; Philippe Plattet
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

4.  Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent.

Authors:  Camille Lévy; Fouzia Amirache; Anais Girard-Gagnepain; Cecilia Frecha; Francisco J Roman-Rodríguez; Ornellie Bernadin; Caroline Costa; Didier Nègre; Alejandra Gutierrez-Guerrero; Lenard S Vranckx; Isabelle Clerc; Naomi Taylor; Lars Thielecke; Kerstin Cornils; Juan A Bueren; Paula Rio; Rik Gijsbers; François-Loïc Cosset; Els Verhoeyen
Journal:  Blood Adv       Date:  2017-10-24

Review 5.  Measles Vaccine.

Authors:  Diane E Griffin
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

6.  Nectin-4-dependent measles virus spread to the cynomolgus monkey tracheal epithelium: role of infected immune cells infiltrating the lamina propria.

Authors:  Marie Frenzke; Bevan Sawatsky; Xiao X Wong; Sébastien Delpeut; Mathieu Mateo; Roberto Cattaneo; Veronika von Messling
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 7.  Development and application of reporter-expressing mononegaviruses: current challenges and perspectives.

Authors:  Darryl Falzarano; Allison Groseth; Thomas Hoenen
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

8.  The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation.

Authors:  D Tien Nguyen; Lot de Witte; Martin Ludlow; Selma Yüksel; Karl-Heinz Wiesmüller; Teunis B H Geijtenbeek; Albert D M E Osterhaus; Rik L de Swart
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

9.  Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters.

Authors:  D Jochmans; S van Nieuwkoop; S L Smits; J Neyts; R A M Fouchier; B G van den Hoogen
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

10.  Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.

Authors:  Tanner S Miest; Marie Frenzke; Roberto Cattaneo
Journal:  Mol Ther       Date:  2013-08-05       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.